Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284141 | 0.84 | APLNR (0.55) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL29129574 | 0.79 | APLNR (0.41) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL11525177 | 0.79 | MEN1 (0.56) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL8520807 | 0.79 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL4150198 | 0.79 | APLNR (0.47) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL1407032 | 0.78 | APLNR (0.43) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL24514107 | 0.77 | APLNR (0.50) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL289320 | 0.77 | APLNR (0.46) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL27891717 | 0.76 | APLNR (0.42) | APLNRGAAMEN1KMT2AMAPK1 | |
| SCHEMBL7122548 | 0.75 | NPSR1 (0.31) | GAATDP1DGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109776464-A | The preparation method of furan tebufenozide, intermediate and preparation method thereof | 江苏省农药研究所股份有限公司 | 2019-05-21 | — | — | CN | claimed |
| CN-113896712-B | Diamide compound containing cyclic amino acid | 华东理工大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-3730494-B1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROLLING AGENT CONTAINING SAME | SUMITOMO CHEMICAL CO (JP) | 2023-11-08 | — | — | EP | disclosed |
| CN-115279767-A | Tetracyclic compounds as inhibitors of hepatitis B surface antigen | 正大天晴药业集团股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114478528-A | Aroyl-substituted tricyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-113896712-A | Diamide compound containing cyclic amino acid | 华东理工大学 | 2022-01-07 | — | — | CN | disclosed |
| CN-110950791-B | Vitamin A and preparation method of vitamin A ester | 万华化学集团股份有限公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210084903-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROLLING AGENT CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | Ichnos Sciences SA (CH) | 2020-11-03 | — | — | US | disclosed |
| WO-2008134397-A1 | AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| CN-1210264-C | 1,3-dialkyl-2-imidazolinones and its prepn. | MITSUI CHEMICALS INC (JP) | 2005-07-13 | — | — | CN | disclosed |
| CN-1256268-A | 1,3-dialkyl-2-imidazolinones and its prepn. | MITSUI CHEMICALS INC (JP) | 2000-06-14 | — | — | CN | disclosed |
| US-6013836-A | PARTICULARLY ACTIVE AGAINST MOTHS AND BEETLES AND THEIR INSECT GROWTH REGULATING ACTIVITY WITHOUT ADVERSE IMPACT ON BENEFICIAL INSECTS; CROPS; FORESTRY | ROHM AND HAAS COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5424333-A | Anthelmintic N'-substituted-N,N'-disubstitutedhydrazines | ROHM AND HAAS COMPANY (US) | 1995-06-13 | — | — | US | disclosed |
| US-5354762-A | Insecticides | ROHM AND HAAS COMPANY (US) | 1994-10-11 | — | — | US | disclosed |
| US-5117057-A | Insecticidal N' substituted-N-N'-disubstituted-hydrazines | ROHM AND HAAS COMPANY (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0261755-A2 | Five-membered heterocyclic derivatives of N'-substituted-N,N'-Diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1988-03-30 | — | — | EP | disclosed |
| EP-0253468-A2 | Six-membered heterocyclic derivatives of N'substituted-N,N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
| EP-0236618-A2 | Insecticidal N'-substituted-N,N'-diacylhydrazines | ROHM AND HAAS COMPANY (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210084903-A1 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD CONTROLLING AGENT CONTAINING SAME | CYC1, C3AR1, CYP4B1 | APLNR 4120/4885GAA 4507/4885MEN1 2112/4885 |
| US-10821100-B2 | Triazolone compounds as mPGES-1 inhibitors | PTGES, PTGS1, PTGIS | APLNR 2818/4885GAA 1319/4885MEN1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.